Literature DB >> 27790457

In vitro Comparison of Generic and Branded Preparations of Amoxicillin with Potassium Clavulanate.

Priyanka Pathak1, Jayshree Dawane2.   

Abstract

INTRODUCTION: The Medical Council of India (MCI) has guidelines for physicians to prescribe drugs with generic names. But physicians and patients might have prejudices against generic drug substitution or concerns regarding quality and generics effectiveness. If the drugs are ineffective, they can result in adverse clinical outcomes such as treatment failure. According to WHO, β-lactams are the most common substandard drugs to be produced amongst antibiotics. AIM: To evaluate and compare invitro efficacy of generic and branded preparations of Amoxicillin with Potassium Clavulanate.
MATERIALS AND METHODS: One generic (C) and 5 branded formulations (A,B,D,E,F) of amoxicillin with potassium clavulanate were taken for microbiological assay. Coding was done. Sterile disks were instilled with 10μl of preparations and disk diffusion was screened by Kirby Bauer Method using Mueller Hinton Agar. Bacterial Strains used were Staphylococcus aureus (S.aureus) and Escherichia Coli. Zone of inhibition was measured. Statistical Analysis was done using repeated measures one-way ANOVA followed by Tukey's test.
RESULTS: Disk Diffusion test showed that branded Drug F has statistically significant less zone of inhibition (p < 0.001) for S. Aureus and (p < 0.05) for E.coli in comparison with generic drug C. Zone of inhibition of branded Drug A, B &amp; E was comparable with the generic drug C.
CONCLUSION: The results of this study indicate that the generic drug tested was equally effective compared to the tested branded drugs except branded Drug D and F. This suggests that efficacy of generic drug is equivalent to branded drugs and maybe used interchangeably with branded drugs.

Entities:  

Keywords:  Antibiotic; Disk diffusion; Microbiological assay

Year:  2016        PMID: 27790457      PMCID: PMC5071957          DOI: 10.7860/JCDR/2016/20009.8466

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  12 in total

1.  Generic Substitution Issues: Brand-generic Substitution, Generic-generic Substitution, and Generic Substitution of Narrow Therapeutic Index (NTI)/Critical Dose Drugs.

Authors:  Marian Sorin Paveliu; Simona Bengea; Fraga Silvia Paveliu
Journal:  Maedica (Buchar)       Date:  2011-01

Review 2.  Update on counterfeit antibiotics worldwide; public health risks.

Authors:  A Delepierre; A Gayot; A Carpentier
Journal:  Med Mal Infect       Date:  2012-05-22       Impact factor: 2.152

3.  Physician perceptions about generic drugs.

Authors:  William H Shrank; Joshua N Liberman; Michael A Fischer; Charmaine Girdish; Troyen A Brennan; Niteesh K Choudhry
Journal:  Ann Pharmacother       Date:  2011-01-04       Impact factor: 3.154

4.  Medical negligence and substandard drugs caused deaths in Indian sterilisation programme, report finds.

Authors:  Sanjeet Bagcchi
Journal:  BMJ       Date:  2015-09-08

5.  Doctors in India defy guidelines on generic drugs.

Authors:  Ganapati Mudur
Journal:  BMJ       Date:  2013-07-01

Review 6.  Antimicrobial susceptibility testing: a review of general principles and contemporary practices.

Authors:  James H Jorgensen; Mary Jane Ferraro
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

Review 7.  Substandard/counterfeit antimicrobial drugs.

Authors:  Theodoros Kelesidis; Matthew E Falagas
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

8.  In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin.

Authors:  Carlos A Rodriguez; Maria Agudelo; Andres F Zuluaga; Omar Vesga
Journal:  BMC Infect Dis       Date:  2010-06-04       Impact factor: 3.090

9.  Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots.

Authors:  Gary J Moet; Amy A Watters; Helio S Sader; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2009-11       Impact factor: 2.803

10.  In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation.

Authors:  Ronald N Jones; Thomas R Fritsche; Gary J Moet
Journal:  Diagn Microbiol Infect Dis       Date:  2008-01-24       Impact factor: 2.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.